1125PPATIENT-REPORTED QUALITY OF LIFE (QOL) WITH SONIDEGIB (LDE225) IN ADVANCED BASAL CELL CARCINOMA (BCC)

R. Dummer1, R. Gutzmer2, M.R. Migden3, L. Dirix4, K. Lewis5, P. Combemale6, K. Higuchi7, S. Gogov8, T. Yi9, R. Herd10, R. Kudchadkar11, U. Trefzer12, J. Lear13, D. Sellami14, A. Guminski15 Department of Dermatology, UniversitatsSpital Zurich, Skin Cancer Center University Hospital, Zurich, SWITZERLAND Department of Dermatology and Allergy, Skin Cancer Center, Medizinische Hochschule Hannover, Hannover, GERMANY Departments of Dermatology and Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Clinical Trials Oncology, Oncologisch Centrum Sint-Augustinus, Antwerp, BELGIUM Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO, USA Oncodermatology Unit, Centre Leon Berard, Lyon, FRANCE Worldwide Health Outcomes, Value, and Access, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Oncology Global Development, Novartis Pharma AG, Basel, SWITZERLAND Biometrics & Data Management, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Department of Dermatology, Glasgow Royal Infirmary, Glasgow, UK Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA Department of Dermatology, Allergology, and Tumor Therapy, Dermatologikum Berlin, Berlin, GERMANY Department of Dermatology, Manchester Royal Infirmary, Manchester, UK Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW, AUSTRALIA